Semaglutide: What the Research Shows
Semaglutide’s clinical trial program spans diabetes and weight management alike. Here’s what the SUSTAIN and STEP trials actually found — and how it stacks up against similar therapies.
Every compound in our catalog is backed by published research — some of it decades old, some of it published this year. This section is where we break that research down in plain language, one compound at a time: what’s been studied, what the findings actually show, and where you can go to read the original source yourself.
We keep this section grounded in what the published literature actually says — not marketing claims, not anecdote. Where the research is early-stage or limited to animal models, we say so.
Semaglutide’s clinical trial program spans diabetes and weight management alike. Here’s what the SUSTAIN and STEP trials actually found — and how it stacks up against similar therapies.
MOTS-C is a mitochondria-encoded peptide tied to metabolism and exercise physiology. Here’s what the research shows — including a rare human exercise-response finding.
BPC-157 and TB-500 are frequently paired in peptide research under the name ‘Wolverine Blend.’ Here’s what’s actually been studied on each compound — and where the evidence stands.
Tirzepatide’s dual-hormone mechanism has driven some of the largest clinical trials in this category. Here’s what the glycemic control and weight management research actually found.
BPC-157 has become one of the most studied peptides in preclinical tissue-repair research. We break down what the tendon, ligament, and gastrointestinal research actually shows — and where you can read the original studies yourself.
You must be at least 21 years of age to access Core Molecular Solutions. By entering this site, you confirm that you meet this requirement